$AGN (Allergan plc)

$AGN {{ '2015-11-04T14:13:36+0000' | timeago}} • Webcast

$AGN's Generics' R&D team has submitted 25 new ANDAs in the US in 2015, with 16 of them potential first to files. The team is on track to submit approx. 35 applications by year-end. Outside the US, $AGN filed over 1,000 marketing authorizations in critical markets.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$AMGN {{ '2017-06-07T14:18:46+0000' | timeago}} • Announcement

$AMGN and $AGN said that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab), on July 13, 2017. Bevacizumab is medication used to treat types of cancers and specific eye disease.

$AGN {{ '2017-06-07T14:08:57+0000' | timeago}} • Announcement

$AGN's subsidiary Allergan Sales LLC agreed to buy privately-held Keller Medical, a medical device company and developer of the Keller Funnel. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures.

$AGN {{ '2017-05-24T14:41:46+0000' | timeago}} • Announcement

$AGN announced the early tender results for tender offers commenced by its subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, and Allergan Inc., each as co-offeror with $AGN's subsidiary Warner Chilcott Ltd., to purchase for cash certain debt securities issued by the entities.

$AGN {{ '2017-05-23T12:27:35+0000' | timeago}} • Announcement

$AGN began an offering of senior unsecured notes in multiple tranches in a registered public offering. The notes will be issued by its indirect subsidiary Allergan Funding SCS and guaranteed by its indirect subsidiaries Warner Chilcott, Allergan Capital and Allergan Finance.

$AGN {{ '2017-05-09T19:02:30+0000' | timeago}} • Webcast

On M&A, $AGN commented that the company is in a strong position currently with no need to do large M&A, with the caveat that it will always be opportunistic. Additionally, $AGN said that the company's focus is on steppingstones and continuing to advance its own strategy.

$AGN {{ '2017-05-09T18:53:46+0000' | timeago}} • Webcast

$AGN's outlook for 2Q17 is higher and expects revenue in the range of $3.9-4Bil. GM for 2Q17 will be lower than 1Q17, largely due to product mix; full quarter for LifeCell, two quarters of ZELTIQ in 2Q17, which has lower GMs. Additionally, Minastrin is having its first full quarter going generic.

$AGN {{ '2017-05-09T18:45:21+0000' | timeago}} • Webcast

$AGN said that regarding RESTASIS IPR and the federal court case, the company has two matters that are coming up in Aug. The company added that it has the hearing on the IPR, and also has the trial in the court in Texas. $AGN anticipate decisions in both of those in the Nov. to Dec. timeframe.

$AGN {{ '2017-05-09T12:41:38+0000' | timeago}} • Infographic

$AGN Allergan plc Earnings AlphaGraphics: Q1 2017 highlights

$AGN {{ '2017-05-09T11:49:54+0000' | timeago}} • Announcement

In 1Q17, $AGN's US Specialized Therapeutics segment net revenues grew 14% YoY to $1.48Bil, driven primarily by growth in Facial Aesthetics, BOTOX Therapeutic and ALLODERM. US General Medicine net revenues were $1.35Bil, down 7%, while International net revenues were $737.3MM, an increase of 10%.

$AGN {{ '2017-05-09T11:43:50+0000' | timeago}} • Announcement

For FY17, $AGN expects net revenue in the range of $15.8-16Bil. GAAP loss per share is predicted to be in range of $9.7-10.2 during this period, while on a non-GAAP basis, it expects to earn $15.85 to $16.35 per share. On a GAAP basis, R&D expense is predicted to be about $2.1Bil.

$AGN {{ '2017-05-09T11:38:01+0000' | timeago}} • Announcement

Pharmaceutical company $AGN swung to a loss of $2.6Bil, or $7.86 per share in 1Q17, from a profit of $186MM, or $0.47 per share a year ago, primarily due to amortization, R&D charges and impairments. Non-GAAP Performance EPS was $3.35. Meanwhile, revenue rose 5% to $3.6Bil during the quarter.

$AGN {{ '2017-05-05T14:37:39+0000' | timeago}} • Announcement

$AGN announced that it is proceeding with its previously initiated cash dividend of $0.70 per ordinary share for 2Q17. The dividend will be paid on June 15, 2017 to shareholders of record at the close of business on May 18, 2017.

$AGN {{ '2017-04-28T17:23:23+0000' | timeago}} • Announcement

$AGN successfully completed the acquisition of Zeltiq Aesthetics, a medical technology company behind a proprietary controlled-cooling fat reducing treatment, CoolSculpting. $AGN acquired Zeltiq Aesthetics for about $2.4Bil in cash.

$AGN {{ '2017-04-18T13:24:49+0000' | timeago}} • Announcement

$AGN entered into a clinical trial agreement with $NVS to conduct a Phase 2b study, using $AGN's cenicriviroc (CVC) and $NVS' lead FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2b study will assess the safety, efficacy and tolerability of this multi-therapy treatment approach for NASH.

$AGN {{ '2017-04-06T22:30:28+0000' | timeago}} • Announcement

$AGN announced that Daphne Karydas will join the company as SVP of Global Investor Relations and Strategy, effective April 17, 2017. Ms. Karydas will report to Tessa Hilado, CFO of $AGN.

$ZLTQ {{ '2017-04-06T12:43:35+0000' | timeago}} • Announcement

$ZLTQ, which agreed to be purchased by $AGN in a $2.47Bil transaction,  is scheduled to hold a stockholder meeting on April 27, 2017 to vote on the proposed transaction. The companies expect the transaction to be completed shortly thereafter.

Recent Transcripts

BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, May 4 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
EXAS (Exact Sciences Corporation)
Thursday, April 27 2017 - 2:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm

AlphaGraphics you may like